Cabio Biotech (Wuhan) Co Ltd
688089
Company Profile
Business description
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
Contact
No. 999, Gaoxin Avenue
East Lake New Technology Development Zone
Hubei Province
Wuhan430075
CHNT: +86 2767845289
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
565
Stocks News & Analysis
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is fairly valued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,117.10 | 303.40 | -3.22% |
| CAC 40 | 8,195.90 | 92.06 | 1.14% |
| DAX 40 | 24,209.42 | 418.77 | 1.76% |
| Dow JONES (US) | 48,750.59 | 249.32 | 0.51% |
| FTSE 100 | 10,571.06 | 209.05 | -1.94% |
| HKSE | 25,249.48 | 1,131.54 | -4.29% |
| NASDAQ | 22,824.15 | 307.46 | 1.37% |
| Nikkei 225 | 54,245.54 | 4,507.85 | -7.67% |
| NZX 50 Index | 13,531.12 | 139.59 | -1.02% |
| S&P 500 | 6,869.78 | 53.15 | 0.78% |
| S&P/ASX 200 | 8,901.20 | 280.50 | -3.05% |
| SSE Composite Index | 4,082.47 | 40.20 | -0.98% |